A New Hypertension Treatment Could Revolutionize Management with Just Two Injections per Year
High blood pressure remains the leading preventable cause of cardiovascular diseases and deaths worldwide. Yet, nearly half of patients fail to control their blood pressure despite available medications. The reasons are many: difficulty adhering to daily treatment, forgetting doses, or reluctance to increase them. An innovative solution is emerging with zilebesiran, an experimental treatment that works differently from conventional drugs.
This new treatment uses a technology called RNA interference. It blocks the production of a key protein in the liver, angiotensinogen, which plays a central role in regulating blood pressure. By sustainably reducing this protein, zilebesiran decreases the amount of a hormone responsible for constricting blood vessels. The result: a significant and prolonged reduction in blood pressure, observable for up to six months after a single subcutaneous injection.
Clinical trials conducted so far show promising results. In patients with mild to moderate hypertension, zilebesiran achieved a reduction in systolic blood pressure of up to 27 mmHg. Unlike traditional medications, which must be taken daily, this treatment could be administered just twice a year. Side effects remain limited, with no major disruption to kidney function or electrolytes, a significant advantage for patients.
The KARDIA-1 and KARDIA-2 studies confirmed its effectiveness, both as a monotherapy and in combination with other antihypertensives. Participants experienced a consistent drop in blood pressure over 24 hours, including at night, which is crucial for preventing cardiovascular complications. Additionally, zilebesiran avoids the sudden drops in blood pressure sometimes seen with other treatments, as it acts gradually and preserves certain local functions of the blood pressure regulatory system.
One of the major strengths of this approach is its simplicity. Fewer medication doses mean better adherence, a recurring issue in hypertension management. Patients could thus benefit from more stable blood pressure control, reducing the risks of strokes or heart attacks. Ongoing trials will assess its long-term efficacy and impact on more diverse populations, particularly those at high risk.
If the results are confirmed, zilebesiran could change the way hypertension is treated. It will not replace healthy habits such as a balanced diet or physical exercise, but it would offer a valuable alternative for those who struggle to adhere to daily treatment. Researchers now await data from Phase III trials to validate its large-scale use and clarify its role in cardiovascular prevention strategies.
Bibliographie
Source de l’étude
DOI : https://doi.org/10.1186/s43044-026-00724-9
Titre : Zilebesiran: an RNA interference agent—its need and potential to transform hypertension treatment
Revue : The Egyptian Heart Journal
Éditeur : Springer Science and Business Media LLC
Auteurs : Sajeet Verma; Akshyaya Pradhan; Prashant Thandi
Source de l’image
Source de l’image non disponible